Riluzole Redesigned to Oral Film

As the first and only riluzole formulation that dissolves on the top of the tongue, EXSERVAN (riluzole) was designed to meet the needs of patients with ALS, including those who have difficulty swallowing some medications.1-3 Advise patients to read the FDA-approved patient labeling (Instructions for Use). Instruct patients to swallow saliva in a normal manner as EXSERVAN dissolves.1

Riluzole Pill Legend

RILUZOLE PILL

EXSERVAN™ Film Legend

EXSERVAN FILM Legend

Not actual size. Size and shape of tablet may vary.

A different way to deliver riluzole

For patients who have difficulty swallowing some medications, EXSERVAN may be an option.1-3

Place EXSERVAN™ on the top of the tongue
  • The first and only oral film formulation of riluzole1
  • Dissolves on the top of the tongue to deliver 50 mg of riluzole1
  • Demonstrated bioequivalence to riluzole tablets (RILUTEK®) with a similar rate of absorption1,3,5
  • Safety and tolerability similar to riluzole tablets1,5

Committed to delivering informative resources to physicians and their patients

EAT-10 screening tool

EAT-10 Screening Tool

Download a tool to help facilitate discussions about your patients' swallowing abilities

>
Get Updates and Request a EXSERVAN™ Rep

Get Updates and Request a Rep

Sign up for email updates and request a visit from a field representative

>
FAQs about EXSERVAN™

FAQs

Find answers to frequently asked questions about EXSERVAN

>

Mitsubishi Tanabe Pharma America, Inc. is committed to advancing treatment options for people living with ALS.

Discover another treatment option to consider in your patients' ALS journeys

Learn More

Learn more about the first and only oral film formulation of riluzole

EXPLORE EXSERVAN
    References:
  1. EXSERVAN (riluzole) Prescribing Information. Jersey City, NJ: Mitsubishi Tanabe Pharma America, Inc.; 2021.
  2. Data on File. Mitsubishi Tanabe Pharma America, Inc., Jersey City, NJ.
  3. Center for Drug Evaluation and Research (US). 2017. EXSERVAN (riluzole). Washington DC: US Food and Drug Administration, Center for Drug and Evaluation Research. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/212640Orig1s000MedR.pdf. Accessed April 2, 2021.
  4. Tomik J, Sowula K, Dworak M, et al. Esophageal peristalsis disorders in ALS patients with dysphagia. Brain Sci. 2020;10(11):820.
  5. RILUTEK® (riluzole) Prescribing Information. Cary, NC: Covis Pharmaceuticals Inc.; 2016.
  6. National Institute of Neurological Disorders and Stroke. Amyotrophic Lateral Sclerosis (ALS) Fact Sheet. https://www.ninds.nih.gov/disorders/patient-caregiver-education/fact-sheets/amyotrophic-lateral-sclerosis-als-fact-sheet. Accessed April 15, 2021.